SuperworthAmphastar Pharmaceuticals profit margin AMPH
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- 10.8%
- Operating margin, 12 months
- 15.7%
- Net margin on a year earlier
- −7.9 pts
- Peer median
- 22.2%
Over the twelve months to Jun 30, 2026, Amphastar Pharmaceuticals kept 10.8% of its revenue as net profit, with an operating margin of 15.7% and a gross margin of 47.7%.
Five years earlier its net margin was 2.7%.
The median for 10 large drugmakers of a similar size is 22.2%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 13.6% | 19.5% | 49.5% |
| FY2024 | 21.8% | 28.1% | 51.1% |
| FY2023 | 21.3% | 30.6% | 54.5% |
| FY2022 | 18.3% | 21.5% | 49.9% |
| FY2021 | 14.2% | 16.0% | 45.6% |
| FY2020 | 0.4% | 3.1% | 41.0% |
| FY2019 | 15.2% | −0.0% | 40.9% |
| FY2018 | −1.9% | −2.9% | 36.3% |
| FY2017 | 1.8% | −0.5% | 37.7% |
| FY2016 | 4.1% | 6.1% | 40.8% |
| FY2015 | −1.1% | −2.7% | 30.8% |
| FY2014 | −5.1% | −8.5% | 24.4% |
| FY2013 | 5.2% | 7.6% | 37.9% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 10.8% | −7.9 pts | 15.7% | |
| Q1 FY26 | 11.0% | −8.4 pts | 16.2% | |
| Q4 FY25 | 13.6% | −8.2 pts | 19.5% | |
| Q3 FY25 | 15.4% | −6.4 pts | 20.7% | |
| Q2 FY25 | 18.6% | −4.7 pts | 25.1% | |
| Q1 FY25 | 19.4% | −3.5 pts | 26.6% | |
| Q4 FY24 | 21.8% | +0.4 pts | 28.1% | |
| Q3 FY24 | 21.8% | −0.7 pts | 29.6% | |
| Q2 FY24 | 23.4% | +4.5 pts | 32.2% | |
| Q1 FY24 | 22.9% | +4.9 pts | 31.3% | |
| Q4 FY23 | 21.3% | +3.0 pts | 30.6% | |
| Q3 FY23 | 22.5% | +6.6 pts | 30.1% |
Against its peers
Companies in Drug Manufacturers - General nearest Amphastar Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| AMPHAmphastar Pharmaceuticals | 10.8% |
| OMEROmeros | n/m |
| ABUSArbutus Biopharma | 84.2% |
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| COLLCollegium Pharmaceutical | 5.9% |
| PAHCPhibro Animal Health | 6.6% |
| ANIPANI Pharmaceuticals | 11.1% |
| CRMDCorMedix | 40.5% |
| ZVRAZevra Therapeutics | 42.8% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| Peer median | 22.2% |
Where Amphastar Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Amphastar Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.